ArticleCellular & molecular immunology2020
BCL-6 suppresses miR-142-3p/5p expression in SLE CD4
Open access · hybridAbstract read
In one paragraph
Article in Cellular & molecular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 43 citations in OpenAlex.
- Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Epigenetic regulation of B cell tolerance and dysfunction in autoimmune disease.Nature reviews. Immunology · 2026Review
- Natural modulators of enhancer of zeste homolog 2 (EZH2): potential epigenetic regulators of aging-associated pathways.Biogerontology · 2026Review
- Epigenetic Alterations in Microbiome-Host Interactions in Inflammatory and Autoimmune Diseases.International journal of molecular sciences · 2026Review
- SETD3 regulates Bcl-6 expression and Tfh differentiation in SLE CD4Clinical epigenetics · 2025Article
- Targeting EZH2 in autoimmune diseases: unraveling epigenetic regulation and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- MicroRNA-142 regulates gut associated lymphoid tissues and group 3 innate lymphoid cells.Mucosal immunology · 2025Article
- RNA modification: a promising code to unravel the puzzle of autoimmune diseases and CD4Frontiers in immunology · 2025Review
- 2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus.Signal transduction and targeted therapy · 2024Article
- Exploring regulatory mechanisms on miRNAs and their implications in inflammation-related diseases.Clinical and experimental medicine · 2024Review
- Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases.Clinical reviews in allergy & immunology · 2024Review
- Helios characterized circulating follicular helper T cells with enhanced functional phenotypes and was increased in patients with systemic lupus erythematosus.Clinical and experimental medicine · 2024Article
- Epigenetic Dysregulation in the Pathogenesis of Systemic Lupus Erythematosus.International journal of molecular sciences · 2024Review
- Identification of Lupus-Associated Genes in the Pathogenesis of Pre-eclampsia Via Bioinformatic Analysis.Bioinformatics and biology insights · 2024Article
- An updated review on abnormal epigenetic modifications in the pathogenesis of systemic lupus erythematosus.Frontiers in immunology · 2024Review
- Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.Molecular therapy oncolytics · 2023Review
- Methyl Donor Micronutrients: A Potential Dietary Epigenetic Target in Systemic Lupus Erythematosus Patients.International journal of molecular sciences · 2023Review
- 3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus.Annals of the rheumatic diseases · 2023Article
- The critical importance of epigenetics in autoimmune-related skin diseases.Frontiers of medicine · 2023Review
- 3D genome organization and epigenetic regulation in autoimmune diseases.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Shu DingDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China.
Qing ZhangDepartment of Dermatology, The Second Xiangya Hospital of Central South University, #139 Renmin Middle Road, 410011, Changsha, Hunan, China.
Shuangyan LuoDepartment of Dermatology, The Second Xiangya Hospital of Central South University, #139 Renmin Middle Road, 410011, Changsha, Hunan, China.
Lihua GaoDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China.
Jinhua HuangDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China.
Jianyun LuDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China.
Jing ChenDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China.
Qinghai ZengDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China.
Aiyuan GuoDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China.
Jinrong ZengDepartment of Dermatology, The Third Xiangya Hospital of Central South University, #138 Tong Zipo Road, 410013, Changsha, Hunan, China. 1203534510@qq.com.
Qianjin LuDepartment of Dermatology, The Second Xiangya Hospital of Central South University, #139 Renmin Middle Road, 410011, Changsha, Hunan, China. qianlu5860@csu.edu.cn.
Central South University · CNSecond Xiangya Hospital of Central South University · CNThird Xiangya Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
The reduced expression of miR-142-3p/5p in CD4
Indexed as
Promoter Regions, GeneticAcetylationAdolescentAdultCase-Control StudiesCD4-Positive T-LymphocytesEnhancer of Zeste Homolog 2 ProteinFemaleHistone DeacetylasesHistonesHumansLupus Erythematosus, SystemicMethylationMicroRNAsMiddle AgedProtein BindingBCL6 protein, humanEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHDAC5 protein, humanHistone DeacetylasesHistonesMicroRNAsMIRN142 microRNA, humanProto-Oncogene Proteins c-bcl-6BCL-6EZH2HDAC5miR-142-3p/5pSLE
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.